Oral semaglutide does not slow the progression of Alzheimer's disease, according to a trial
Oral semaglutide is not effective in slowing the progression of the disease in patients with mild Alzheimer’s disease, according to the findings of the first large-scale, randomised phase 3 clinical trials published in The Lancet. In these trials, around 3,800 patients aged between 55 and 85 with a confirmed diagnosis and mild symptoms received up to 14 mg daily of oral semaglutide or a placebo. After two years, no significant difference in disease progression was observed.
0